Scribe Therapeutics kicked off the second-half IPO window with a rare gene editing listing priced above earlier expectations. The company’s offering comes after more than two years without new gene-editing IPOs and arrives as the market continues to reward manufacturing- and development-readiness in platform-driven companies. Scribe framed the funding as support for in vivo genetic medicine, focused initially on common chronic cardiometabolic conditions. Its strategy centers on using CRISPR-based approaches to modulate gene expression without permanent genome edits. The IPO’s scale and timing highlight how investors are underwriting gene-based modalities when they can demonstrate early clinical momentum and clear target biology, particularly in cardiovascular risk areas with established therapeutic benchmarks. With the company’s lead candidate progressing in first clinical testing and additional assets planned for early-stage advancement, the listing sets expectations for near-term data catalysts in 2027.